微芯生物：新品放量加速，前三季度盈利7077万元

Core Viewpoint - Microchip Biotech (688321.SH) reported a significant increase in revenue and profit for Q3 2025, driven by strong sales of its innovative drugs, particularly Sidabone and Siglitazone [1] Financial Performance - For the first three quarters of 2025, the company achieved a revenue of 674 million yuan, representing a year-on-year growth of 40.12% [1] - In Q3 2025, the company generated a revenue of 268 million yuan, showing a year-on-year increase of 50% and a quarter-on-quarter growth of 10% [1] - The quarterly profit expanded to 41.18 million yuan, with total profit for the first three quarters reaching 70.77 million yuan [1] Product Performance - The growth in revenue is primarily attributed to the sales of Sidabone, which saw a year-on-year revenue increase of 18.76%, and Siglitazone, which experienced a remarkable year-on-year revenue growth of 136.13% [1] - Microchip Biotech has successfully launched two first-in-class innovative drugs, Sidabone (Aipusha®) and Siglitazone (Shuangluoping®), in multiple markets including mainland China, Japan, and Taiwan [1] Industry Recognition - The company has been recognized as a leading biotech firm at the 2025 China Pharmaceutical Decision-Makers Summit and received an award for Siglitazone as an industry-leading innovative drug [1]